Try a new search

Format these results:

Searched for:

person:leep05

in-biosketch:yes

Total Results:

215


Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies

Zhao, Yani; Deng, Fang-Ming; Huang, Hongying; Lee, Peng; Lepor, Hebert; Rosenkrantz, Andrew B; Taneja, Samir; Melamed, Jonathan; Zhou, Ming
CONTEXT/BACKGROUND:- In Gleason score GS (7) prostate cancers, the quantity of Gleason pattern 4 (GP 4) is an important prognostic factor and influences treatment decisions. Magnetic resonance imaging (MRI)-targeted biopsy has been increasingly used in clinical practice. OBJECTIVE:- To investigate whether MRI-targeted biopsy may detect GS 7 prostate cancer with greater GP 4 quantity, and whether it improves biopsy/radical prostatectomy GS concordance. DESIGN/METHODS:- A total of 243 paired standard and MRI-targeted biopsies with cancer in either standard or targeted or both were studied, 65 of which had subsequent radical prostatectomy. The biopsy findings, including GS and tumor volume, were correlated with the radical prostatectomy findings. RESULTS:- More prostate cancers detected by MRI-targeted biopsy were GS 7 or higher. Mean GP 4 percentage in GS 7 cancers was 31.0% ± 29.3% by MRI-targeted biopsy versus 25.1% ± 29.5% by standard biopsy. A total of 122 of 218 (56.0%) and 96 of 217 (44.2%) prostate cancers diagnosed on targeted biopsy and standard biopsy, respectively, had a GP 4 of 10% or greater ( P = .01). Gleason upgrading was seen in 12 of 59 cases (20.3%) from MRI-targeted biopsy and in 24 of 57 cases (42.1%) from standard biopsy ( P = .01). Gleason upgrading correlated with the biopsy cancer volume inversely and GP 4 of 30% or less in standard biopsy. Such correlation was not found in MRI-targeted biopsy. CONCLUSIONS:- Magnetic resonance imaging-targeted biopsy may detect more aggressive prostate cancers and reduce the risk of Gleason upgrading in radical prostatectomy. This study supports a potential role for MRI-targeted biopsy in the workup of prostate cancer and inclusion of percentage of GP 4 in the prostate biopsy reports.
PMID: 29965785
ISSN: 1543-2165
CID: 3186052

STAT3 Phosphorylation at Ser727 is involved in prostate carcinogenesis and is associated with increased disease-associated mortality [Meeting Abstract]

Chen, Fei; Ren, Qinghu; Levy, David; Lee, Peng; Deng, Fangming; Melamed, Jonathan
ISI:000478081101279
ISSN: 0023-6837
CID: 4048362

Integrated Expression (Chromogenic in situ Hybridization) of Long Noncoding RNAs (LncRNAs) Segregate Low Grade from Clinically Significant Prostate Cancer [Meeting Abstract]

Parimi (Parini), Vamsi; Xia, Yuhe; Mezzano, Valeria; Vasudevaraja, Varshini; Selvaraj, Shanmugapriya; Loomis, Cynthia; Moreira, Andre; Lee, Peng; Levy, David; Park, Kyung; Huang, Hongying; Ren, Qinghu; Deng, Fangming; Melamed, Jonathan
ISI:000478081101389
ISSN: 0023-6837
CID: 4048382

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

Guida, Florence; Sun, Nan; Bantis, Leonidas E; Muller, David C; Li, Peng; Taguchi, Ayumu; Dhillon, Dilsher; Kundnani, Deepali L; Patel, Nikul J; Yan, Qingxiang; Byrnes, Graham; Moons, Karel G M; Tjønneland, Anne; Panico, Salvatore; Agnoli, Claudia; Vineis, Paolo; Palli, Domenico; Bueno-de-Mesquita, Bas; Peeters, Petra H; Agudo, Antonio; Huerta, Jose M; Dorronsoro, Miren; Barranco, Miguel Rodriguez; Ardanaz, Eva; Travis, Ruth C; Byrne, Karl Smith; Boeing, Heiner; Steffen, Annika; Kaaks, Rudolf; Hüsing, Anika; Trichopoulou, Antonia; Lagiou, Pagona; La Vecchia, Carlo; Severi, Gianluca; Boutron-Ruault, Marie-Christine; Sandanger, Torkjel M; Vainio, Elisabete Weiderpass; Nøst, Therese H; Tsilidis, Kostas; Riboli, Elio; Grankvist, Kjell; Johansson, Mikael; Goodman, Gary E; Feng, Ziding; Brennan, Paul; Johansson, Mattias; Hanash, Samir M
Importance/UNASSIGNED:There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective/UNASSIGNED:To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants/UNASSIGNED:Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Main Outcomes and Measures/UNASSIGNED:Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). Results/UNASSIGNED:In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. Conclusions and Relevance/UNASSIGNED:This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
PMID: 30003238
ISSN: 2374-2445
CID: 3200242

Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence

Bainor, Anthony J; Deng, Fang-Ming; Wang, Yu; Lee, Peng; Cantor, David J; Logan, Susan K; David, Gregory
Distinguishing between indolent and aggressive prostate adenocarcinoma (PCa) remains a priority to accurately identify patients who need therapeutic intervention. SIN3B has been implicated in the initiation of senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier to malignant progression. SIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive PCa. Furthermore, SIN3B was downregulated in human PCa correlating with upregulation of its target genes. Our results suggest a tumor suppressor function for SIN3B that limits PCa progression, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.
PMCID:5626631
PMID: 28807943
ISSN: 1538-7445
CID: 2670812

Gleason Score 7 and 8 Prostate Cancer with Cribriform Morphology Diagnosed in Prostate Biopsy Is More Likely to Have Seminal Vesicle Invasion and Pelvic Lymph Node Metastasis in Radical Prostatectomy [Meeting Abstract]

Wang, Ling; Deng, Fang-Ming; Huang, Hongying; Lee, Peng; Melamed, Jonathan; Zhou, Ming
ISI:000393724401340
ISSN: 1530-0307
CID: 2506732

Comparison of Standard and MRI Targeted Biopsy in Anterior Predominant Prostate Cancer [Meeting Abstract]

Peng, Yu-Ching; Wang, Ying; Huang, Hongying; Lee, Peng; Melamed, Jonathan; Zhou, Ming; Deng, Fang-Ming
ISI:000393724401274
ISSN: 1530-0307
CID: 2506722

Gleason Score 3+4=7 Prostate Carcinomas Detected by MRI-Targeted Biopsies Contain Higher Percentage of Pattern 4 and Are Less Likely to Be Upgraded in Radical Prostatectomies [Meeting Abstract]

Zhao, Yani; Deng, Fang-Ming; Huang, Hongying; Lee, Peng; Melamed, Jonathan; Zhou, Ming
ISI:000393724401366
ISSN: 1530-0307
CID: 2506762

Clinical Significance of Tertiary Pattern 4 in Gleason 3+3=6 Adenocarcinoma of the Prostate [Meeting Abstract]

Barna, Nicholas; Ettel, Mark; Chen, Fei; Lee, Peng; Huang, Hongying; Melamed, Jonathan; Zhou, Ming; Deng, Fang-Ming
ISI:000393724401129
ISSN: 1530-0307
CID: 2506702

Comparison of Standard and MRI Targeted Biopsy in Anterior Predominant Prostate Cancer [Meeting Abstract]

Peng, Yu-Ching; Wang, Ying; Huang, Hongying; Lee, Peng; Melamed, Jonathan; Zhou, Ming; Deng, Fang-Ming
ISI:000394467301274
ISSN: 1530-0285
CID: 2517542